Kymera Therapeutics Inc. Common Stock (KYMR)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see a speculative clinical-stage biotech. At the 2026-10-26 close of $114.84, Kymera has a $9.5B market cap, while FairStock calculations show a negative P/E of -35.34, P/B of 6.30, ROE of -24.15%, ROCE of -15.59%, and a 23/100 score. The filed numbers explain the skepticism: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $65.0M and net loss $61.2M, or EPS -$0.62; fiscal Q1 2026 had $34.4M revenue and a $69.2M net loss. Full-year losses widened from $147.0M in FY2023 to $223.9M in FY2024 and $311.4M in FY2025, while revenue fell from $78.6M to $47.1M to $39.2M. Trailing free cash flow is -$238.0M, a -2.5% FCF yield. The balance sheet looks low-levered with D/E of 0.05, and FairStock’s Altman Z-score of 39.93 suggests little near-term solvency stress on the supplied data, though Piotroski is 4/9. Business quality rests on KT-621 in Phase 2b and KT-579 in Phase 1; any moat must come from future clinical success and intellectual property, not current profits. FairStock’s Lynch category is none because losses occurred in each of the last four years. Revenue in fiscal Q2 2026 was far above fiscal Q2 2025’s $11.5M, but annual revenue is uneven and losses are heavy. This is a clinical-story valuation, not a Graham bargain; at 6.30 times book with negative earnings, the price already assumes major pipeline success.

In plain English: Kymera is a clinical-stage biotech that is trying to make oral medicines that remove disease-causing proteins. It is not profitable, has lost money in each of the last four years, and burns cash, so the business looks financially weak today. At $114.84, the stock looks expensive relative to its losses and assets; it is a high-risk clinical-story stock rather than a proven earnings compounder.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer